Anti-Diabetes Drugs - Estonia | Statista Market Forecast

The Estonian market for Anti-Diabetes Drugs market is anticipated to witness a significant revenue growth, with projections indicating that it will reach US$16.26m in 2024.
Furthermore, this revenue is expected to demonstrate a promising annual growth rate (CAGR 2024-2029) of 7.43%, ultimately leading to a market volume of US$23.26m by 2029.
When compared globally, it is worth noting that United States is anticipated to generate the highest revenue in this market, amounting to an impressive US$37.84bn in 2024.
Estonia's growing healthcare infrastructure and emphasis on preventative care is driving an increased demand for innovative anti-diabetes drugs in the country.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Estonia has shown steady growth in recent years.

Customer preferences: Estonia has a high prevalence of diabetes, with an estimated 10% of the population suffering from the disease. This has led to a high demand for anti-diabetes drugs in the country. Patients in Estonia prefer drugs that are effective, affordable, and have minimal side effects. They also prefer drugs that are easy to use and do not require frequent dosage adjustments.

Trends in the market: The anti-diabetes drugs market in Estonia has been growing steadily due to an increase in the number of patients diagnosed with diabetes. The market is dominated by big pharmaceutical companies that offer a wide range of anti-diabetes drugs. There has also been a growing trend towards the use of combination therapies, where two or more drugs are used together to achieve better glycemic control.

Local special circumstances: Estonia has a well-developed healthcare system, with a high level of access to healthcare services. The government provides subsidies for anti-diabetes drugs, making them more affordable for patients. There has also been a growing trend towards the use of digital health solutions, such as mobile apps and telemedicine, to improve diabetes management.

Underlying macroeconomic factors: Estonia has a stable economy, with a high level of economic freedom and a well-educated workforce. The country has a strong pharmaceutical industry, with a number of local companies producing generic drugs. The government has been investing in healthcare infrastructure and technology, which has helped to improve diabetes management in the country.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.